A landscape of driver mutations in melanoma

Hodis, Eran, Watson, Ian R., Kryukov, Gregory V., Arold, Stefan T., Imielinski, Marcin, Theurillat, Jean-Philippe, Nickerson, Elizabeth, Auclair, Daniel +32 more·2012·Cell
DOI 10.1016/j.cell.2012.06.024

Cited by (1,006)

Items 601–700 of 1,006

  1. Positive Association Between Location of Melanoma, Ultraviolet Signature, Tumor Mutational Burden, and Response to Anti–PD-1 Therapy
    L. Dousset, F. Poizeau, Caroline Robert, Sandrine Mansard, Laurent Mortier, Charline Caumont, Émilie Routier, Alain Dupuy, Jacques Rouanet, Maxime Battistella et al. · 2021 · JCO Precision Oncology
  2. Intratumoral heterogeneity: Clonal cooperation in epithelial-to-mesenchymal transition and metastasis
    Deepika Neelakantan, David J Drasin, Heide L. Ford · 2014 · Cell Adhesion & Migration
  3. Protein and non-protein biomarkers in melanoma: a critical update
    Nadine Tandler, Birgit Mosch, Jens Pietzsch · 2012 · Amino Acids
  4. The Multiple Facets of PRC2 Alterations in Cancers
    Michel Adam Wassef, Raphaël Margueron · 2016 · Journal of Molecular Biology
  5. A dynamic mechanism for allosteric activation of Aurora kinase A by activation loop phosphorylation
    Emily F. Ruff, Joseph M. Muretta, Andrew R. Thompson, Eric W. Lake, Soreen Cyphers, Steven K. Albanese, Sonya M. Hanson, Julie M. Behr, David Dale Thomas, John D. Chodera et al. · 2018 · eLife
  6. Diagnostic Cancer Genome Sequencing and the Contribution of Germline Variants
    Outi Kilpivaara, Lauri A. Aaltonen · 2013 · Science
  7. Patterns of genomic evolution in advanced melanoma
    Einar Elvbakken Birkeland, S. Zhang, Deepak Balakrishnan Poduval, Jürgen Geisler, Sigve Nakken, Daniel Vodák, Leonardo A. Meza‐Zepeda, Eivind J. Hovig, Ola Myklebost, Stian Knappskog et al. · 2018 · Nature Communications
  8. Stepwise-edited, human melanoma models reveal mutations’ effect on tumor and microenvironment
    Eran Hodis, Elena Torlai Triglia, John Kwon, Tommaso Biancalani, Labib R. Zakka, Saurabh Parkar, Jan-Christian Hütter, Lorenzo Buffoni, Toni Marie Delorey, Devan Phillips et al. · 2022 · Science
  9. Immunotherapy of melanoma
    John B.A.G. Haanen · 2013 · European Journal of Cancer Supplements
  10. Regulating Cdc42 and Its Signaling Pathways in Cancer: Small Molecules and MicroRNA as New Treatment Candidates
    Xinghua Xiao, Linchen Lv, Jing Duan, Yemeng Wu, Shujin He, Zhenzhen Hu, Lixia Xiong · 2018 · Molecules
  11. The multifaceted allosteric regulation of Aurora kinase A
    Nicholas M. Levinson · 2018 · Biochemical Journal
  12. The Epigenetic Regulator I-BET151 Induces BIM-Dependent Apoptosis and Cell Cycle Arrest of Human Melanoma Cells
    Stuart J. Gallagher, Branka Mijatov, Dilini Gunatilake, Jessamy C. Tiffen, Kavitha Gowrishankar, Lei Jin, Gulietta M. Pupo, Carleen M. Cullinane, Rab K. Prinjha, Nicholas N. Smithers et al. · 2014 · Journal of Investigative Dermatology
  13. A novel spheroid-based co-culture model mimics loss of keratinocyte differentiation, melanoma cell invasion, and drug-induced selection of ABCB5-expressing cells
    Julia Klicks, Christoph Maßlo, Mark A. Kluth, Rüdiger Rudolf, Mathias Hafner · 2019 · BMC Cancer
  14. Genetic Alterations in the INK4a/ARF Locus: Effects on Melanoma Development and Progression
    Zizhen Ming, Su Yin Lim, Helen Rizos · 2020 · Biomolecules
  15. Alpha-melanocyte stimulating hormone (α-MSH): biology, clinical relevance and implication in melanoma
    Luigi Dall’Olmo, Nicole Papa, Nicoletta Concetta Surdo, Ilaria Marigo, Simone Mocellin M. D · 2023 · Journal of Translational Medicine
  16. MTSS1 is a metastasis driver in a subset of human melanomas
    Kirsten D. Mertz, Gaurav Pathria, Christine Wagner, Juha Saarikangas, Andrea Sboner, Julia Romanov, Melanie Gschaider, Florian Lenz, Friederike Neumann, Wolfgang Schreiner et al. · 2014 · Nature Communications
  17. Genetic progression of malignant melanoma
    József Tı́már, Laura Vízkeleti, Viktória Doma, Tamás Barbai, Erzsébet Rásó · 2016 · Cancer and Metastasis Reviews
  18. Rnd3 in Cancer: A Review of the Evidence for Tumor Promoter or Suppressor
    Lisa Paysan, Léo Piquet, Frédéric Saltel, Violaine Moreau · 2016 · Molecular Cancer Research
  19. Prognostic impact and concordance of TERT promoter mutation and protein expression in matched primary and metastatic cutaneous melanoma
    Emilia Hugdahl, May Britt Kalvenes, Monica Mannelqvist, Rita Grude Ladstein, Lars A. Akslen · 2017 · British Journal of Cancer
  20. Activated Rho GTPases in Cancer—The Beginning of a New Paradigm
    Pontus Aspenström · 2018 · International Journal of Molecular Sciences
  21. Rho GTPases and cancer
    Hui Li, Karine Peyrollier, Gülcan Kilic, Cord Brakebusch · 2013 · BioFactors
  22. Conjunctival melanoma copy number alterations and correlation with mutation status, tumor features, and clinical outcome
    Nihal Kenawy, Helen Kalirai, Joseph J. Sacco, Sarah L. Lake, Steffen Heegaard, Ann‐Cathrine Larsen, Paul T. Finger, Tatyana Milman, Kimberly J. Chin, Carlo Mosci et al. · 2019 · Pigment Cell & Melanoma Research
  23. The Anti-Melanoma Activity of Dinaciclib, a Cyclin-Dependent Kinase Inhibitor, Is Dependent on p53 Signaling
    Brijal M. Desai, Jessie Villanueva, Thierry-Thien K. Nguyen, Mercedes Lioni, Min Xiao, Jun Kong, Clemens Krepler, Adina Vultur, Keith T. Flaherty, Katherine L. Nathanson et al. · 2013 · PLoS ONE
  24. PDK1 and SGK3 contribute to the growth of BRAF mutant melanomas and are potential therapeutic targets
    M. Scortegagna, E. Lau, Tong-Wu Zhang, Yong-Mei Feng, C. Sereduk, Hong-Wei Yin, S. De, K. Meeth, James Platt, C. Langdon et al. · 2015 · Cancer Research
  25. Spitz nevi and Spitzoid melanomas: exome sequencing and comparison with conventional melanocytic nevi and melanomas
    Rossitza Z. Lazova, Natapol Pornputtapong, Ruth Halaban, Marcus Bosenberg, Yalai Bai, Hao Chai, Michael O. Krauthammer · 2017 · Modern Pathology
  26. A water-mediated allosteric network governs activation of Aurora kinase A
    Soreen Cyphers, Emily F. Ruff, Julie M. Behr, John D. Chodera, Nicholas M. Levinson · 2017 · Nature Chemical Biology
  27. Targeting negative regulation of p53 by MDM2 and WIP1 as a therapeutic strategy in cutaneous melanoma
    Chiao‐En Wu, Arman Esfandiari, Yi-Hsuan Ho, Nan Wang, Ahmed Khairallah Mahdi, Erhan Aptullahoğlu, Penny E. Lovat, John Lunec · 2017 · British Journal of Cancer
  28. Rho-mediated signaling promotes BRAF inhibitor resistance in de-differentiated melanoma cells
    Sean A. Misek, Kate M. Appleton, Thomas Steven Dexheimer, Erika Mathes Lisabeth, Roger S. Lo, Scott D. Larsen, Kathleen A. Gallo, Richard R. Neubig · 2019 · Oncogene
  29. Inhibition of autophagy enhances the effects of the <scp>AKT</scp> inhibitor <scp>MK</scp>‐2206 when combined with paclitaxel and carboplatin in <i><scp>BRAF</scp></i> wild‐type melanoma
    Rebecca, Vito W., Massaro, Renato R., Fedorenko, Inna V., Sondak, Vernon K., Anderson, Alexander R. A., Kim, Eunjung, Amaravadi, Ravi K., Maria‐Engler, Silvya S., Messina, Jane L., Gibney, Geoffrey T. et al. · 2014 · Pigment Cell &amp; Melanoma Research
  30. Genetic and epigenetic alterations of micro RNA s and implications for human cancers and other diseases
    Musaffe Tuna, Andreia S. Machado, George A. Călin · 2015 · Genes Chromosomes and Cancer
  31. The complex relationship between MITF and the immune system: a Melanoma ImmunoTherapy (response) Factor?
    Robert Ballotti, Yann Chéli, Corine Bertolotto · 2020 · Molecular Cancer
  32. The α‐melanocyte‐stimulating hormone/melanocortin‐1 receptor interaction: A driver of pleiotropic effects beyond pigmentation
    Cecilia Herráiz, Idoya Martínez‐Vicente, Vittoria Maresca · 2021 · Pigment Cell & Melanoma Research
  33. Melanoma therapeutics: a literature review
    Pavan Kumar Dhanyamraju, Trupti Patel · 2022 · Journal of Biomedical Research
  34. Targeted-capture massively-parallel sequencing enables robust detection of clinically informative mutations from formalin-fixed tumours
    Stephen Q. Wong, Jason Li, Renato Salemi, Karen E. Sheppard, Hongdo Do, Richard W. Tothill, Grant A. McArthur, Alexander Dobrovic · 2013 · Scientific Reports
  35. Genome‐wide promoter methylation analysis identifies epigenetic silencing of MAPK 13 in primary cutaneous melanoma
    Linda Y. Gao, Marjon A. Smit, Joost J. van den Oord, Jelle J. Goeman, Els M.E. Verdegaal, Sjoerd H. van der Burg, Marguerite Stas, Samuel Beck, Nelleke A. Gruis, Cornelis P. Tensen et al. · 2013 · Pigment Cell & Melanoma Research
  36. PI3′-Kinase Inhibition Forestalls the Onset of MEK1/2 Inhibitor Resistance in <i>BRAF</i> -Mutated Melanoma
    Deuker, Marian M., Marsh Durban, Victoria, Phillips, Wayne A., McMahon, Martin · 2015 · Cancer Discovery
  37. Mutation status among patients with sinonasal mucosal melanoma and its impact on survival
    M. Amit, S. Tam, A. Abdelmeguid, Dianna Roberts, Y. Takahashi, S. Raza, Shirley Y. Su, M. Kupferman, F. DeMonte, E. Hanna · 2017 · British Journal of Cancer
  38. Ligand-activated BMP signaling inhibits cell differentiation and death to promote melanoma
    Arvind M. Venkatesan, Rajesh Vyas, Alec K. Gramann, Karen Dresser, Sharvari Gujja, Sanchita Bhatnagar, Sagar Chhangawala, Camilla Borges Ferreira Gomes, Hualin Simon Xi, Christine Guo Lian et al. · 2017 · Journal of Clinical Investigation
  39. BRN 2, a POU erful driver of melanoma phenotype switching and metastasis
    Mitchell E. Fane, Yash Chhabra, Aaron G. Smith, Richard A. Sturm · 2018 · Pigment Cell & Melanoma Research
  40. Cyclin D1 expression and novel mutational findings in Rosai‐Dorfman disease
    Ezra G. Baraban, Sam Sadigh, Jason N. Rosenbaum, John Van Arnam, Agata M. Bogusz, Chelsea R. Mehr, Adam Bagg · 2019 · British Journal of Haematology
  41. Genomic Characterization of Dysplastic Nevi Unveils Implications for Diagnosis of Melanoma
    Melamed, Rachel D., Aydin, Iraz T., Rajan, Geena Susan, Phelps, Robert, Silvers, David N., Emmett, Kevin J., Brunner, Georg, Rabadan, Raul, Celebi, Julide Tok · 2017 · Journal of Investigative Dermatology
  42. Patterns and processes of somatic mutations in nine major cancers
    Peilin Jia, William J. Pao, Zhongming Zhao · 2014 · BMC Medical Genomics
  43. A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain Metastases
    James J. Harding, Federica Catalanotti, Rodrigo Ramella Munhoz, Donavan T. Cheng, Amin Yaqubie, Nicole E. Kelly, Gregory C McDermott, Romona D. Kersellius, Taha Merghoub, Mario E. Lacouture et al. · 2015 · The Oncologist
  44. Nano-enabled photosynthesis in tumours to activate lipid peroxidation for overcoming cancer resistances
    Jun Jiang, Weili Wang, Huizhen Zheng, Xiao Chen, Xi Liu, Qianqian Xie, Xiaoming Cai, Zengli Zhang, Ruibin Li · 2022 · Biomaterials
  45. Targeting TBK1 Inhibits Migration and Resistance to MEK Inhibitors in Mutant NRAS Melanoma
    Ha Linh Vu, Andrew E. Aplin · 2014 · Molecular Cancer Research
  46. Metastatic pathways in patients with cutaneous melanoma
    Nikki Rae Adler, Andrew Mark Haydon, Catriona McLean, John William Kelly, Victoria Mar · 2016 · Pigment Cell & Melanoma Research
  47. Molecular genetics of cutaneous squamous cell carcinoma: perspective for treatment strategies
    Lucia Di Nardo, Cristina Pellegrini, Alessandro Di Stefani, Laura Del Regno, Pietro Sollena, Alfredo Piccerillo, Caterina Longo, Claus Garbe, Maria Concetta Fargnoli, Ketty Peris · 2019 · Journal of the European Academy of Dermatology and Venereology
  48. The Evolution of Melanoma Resistance Reveals Therapeutic Opportunities
    Meghna Das Thakur, Darrin D. Stuart · 2013 · Cancer Research
  49. Functional Genomic Screening Independently Identifies CUL3 as a Mediator of Vemurafenib Resistance via Src-Rac1 Signaling Axis
    Marion Vanneste, Charlotte R. Feddersen, Afshin Varzavand, Elliot Y. Zhu, Tyler M. Foley, Lei Qiang Zhao, Kathleen H. Holt, Mohammed M. Milhem, Robert C. Piper, Christopher S. Stipp et al. · 2020 · Frontiers in Oncology
  50. Exploiting epigenetic dependencies in ovarian cancer therapy
    Aisling Y. Coughlan, Giuseppe Testa · 2021 · International Journal of Cancer
  51. The functional relevance of somatic synonymous mutations in melanoma and other cancers
    Valer Gotea, Jared J. Gartner, Nouar Qutob, Laura L. Elnitski, Yardena Samuels · 2015 · Pigment Cell & Melanoma Research
  52. MSEA: detection and quantification of mutation hotspots through mutation set enrichment analysis
    Peilin Jia, Quan Wang, Qingxia Chen, Katherine E. Hutchinson, William J. Pao, Zhongming Zhao · 2014 · Genome biology
  53. Quantitative phosphoproteomics reveals new roles for the protein phosphatase PP6 in mitotic cells
    Scott F. Rusin, Kate A. Schlosser, Mark E. Adamo, Arminja Nadine Kettenbach · 2015 · Science Signaling
  54. Truncating PREX2 mutations activate its GEF activity and alter gene expression regulation in NRAS-mutant melanoma
    Yonathan Lissanu, Yanxia Shi, Kunal Rai, Luigi Nezi, Samirkumar B. Amin, Chia-Chin Wu, Kadir Caner Akdemir, Mozhdeh Mahdavi, Qian Peng, Qing Chang et al. · 2016 · Proceedings of the National Academy of Sciences
  55. Whole-Exome Sequencing Reveals Frequent Mutations in Chromatin Remodeling Genes in Mammary and Extramammary Paget’s Diseases
    Guohong Zhang, Songxia Zhou, Weixiang Zhong, Liangli Hong, Yuanyuan Wang, Shanming Lu, Jiankai Pan, Yuansheng Huang, Mingwan Su, Richard Ian Crawford et al. · 2018 · Journal of Investigative Dermatology
  56. Evolving neoantigen profiles in colorectal cancers with DNA repair defects
    Giuseppe Rospo, Annalisa Lorenzato, Nabil Amirouchene-Angelozzi, Alessandro Magrì, Carlotta Cancelliere, Giorgio Corti, Carola Negrino, Vito Amodio, Monica Montone, Alice Bartolini et al. · 2019 · Genome Medicine
  57. Mutation of the PTCH1 gene predicts recurrence of breast cancer
    Chih‐Yang Wang, Yung-Chieh Chang, Yao‐Lung Kuo, Kuo‐Ting Lee, Pai‐Sheng Chen, Chun Hei Antonio Cheung, Chih‐Peng Chang, Nam Nhut Phan, Meng‐Ru Shen, Hui‐Ping Hsu · 2019 · Scientific Reports
  58. Tissue specificity of DNA damage response and tumorigenesis
    Siman Sun, Michael D. Osterman, Mo Li · 2019 · Cancer Biology and Medicine
  59. Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas
    Alexander Noor Shoushtari, Walid Khaled Chatila, Arshi Arora, Francisco Sánchez-Vega, Havish Sairaju Kantheti, Jorge A. Rojas Zamalloa, Penina Krieger, Margaret K. Callahan, Allison Betof Warner, Michael Andrew Postow et al. · 2021 · Clinical Cancer Research
  60. WASP family proteins: Molecular mechanisms and implications in human disease
    Kramer, Daniel A., Piper, Hannah K., Chen, Baoyu · 2022 · European Journal of Cell Biology
  61. BCL-xL inhibition potentiates cancer therapies by redirecting the outcome of p53 activation from senescence to apoptosis
    Vijaya Bharti, Reese Watkins, Amrendra Kumar, Rebecca L. Shattuck-Brandt, Alexis Mossing, Arjun Mittra, Chengli Shen, Allan Tsung, Alexander E. Davies, Walter G. Hanel et al. · 2022 · Cell Reports
  62. Epigenetics and Oncology
    Padmaja Mummaneni, Stacy Shifflett Shord · 2014 · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
  63. Molecular characterisation of cutaneous melanoma: creating a framework for targeted and immune therapies
    Shivshankari Rajkumar, Ian R. Watson · 2016 · British Journal of Cancer
  64. Tuberous sclerosis complex inactivation disrupts melanogenesis via mTORC1 activation
    Juxiang Cao, Magdalena Ewa Tyburczy, Joel Moss, Thomas N. Darling, Hans R. Widlund, David J. Kwiatkowski · 2016 · Journal of Clinical Investigation
  65. Uveal Melanoma Metastasis
    Ernesto Rossi, Michela Croce, Francesco Reggiani, Giovanni Schinzari, Marianna Ambrosio, Rosaria M. R. Gangemi, Giampaolo Tortora, Ulrich Pfeffer, Adriana Agnese Amaro · 2021 · Cancers
  66. The dynamics of Rho GTPase signaling and implications for targeting cancer and the tumor microenvironment
    Marina Pajic, David Herrmann, Claire Vennin, James R. W. Conway, Venessa T. Chin, Anna‐Karin Johnsson, Heidi C. E. Welch, Paul Timpson · 2015 · Small GTPases
  67. Targeted next-generation sequencing reveals high frequency of mutations in epigenetic regulators across treatment-naïve patient melanomas
    Jonathan J. Lee, Lynette Marie Sholl, Neal Ian Lindeman, Scott R. Granter, Alvaro C. Laga, Priyanka Shivdasani, Gary Chin, Jason J. Luke, Patrick Alexander Ott, Frank Stephen Hodi et al. · 2015 · Clinical Epigenetics
  68. Synergy from gene expression and network mining (SynGeNet) method predicts synergistic drug combinations for diverse melanoma genomic subtypes
    Kelly Regan, Jielin Xu, Mallory J. DiVincenzo, Megan Christina Duggan, Reena Shakya, Ryejung Na, William Edgar Carson, Philip Payne, Fuhai Li · 2019 · npj Systems Biology and Applications
  69. Distinct Mutation Patterns Reveal Melanoma Subtypes and Influence Immunotherapy Response in Advanced Melanoma Patients
    Franz J. Hilke, Tobias W. Sinnberg, Axel Gschwind, Heike Niessner, German M. Demidov, Teresa Maria Santos Amaral, Stephan Ossowski, Irina Bonzheim, Martin Röcken, Olaf Rieß et al. · 2020 · Cancers
  70. Heterogeneity in Melanoma
    Mei Fong Ng, Jacinta L. Simmons, Glen M. Boyle · 2022 · Cancers
  71. Pharmacological targeting of the cancer epigenome
    Nathaniel W. Mabe, Jennifer A. Perry, Clare F. Malone, Kimberly Stegmaier · 2024 · Nature Cancer
  72. EZH 2: an emerging role in melanoma biology and strategies for targeted therapy
    Jessamy C. Tiffen, Stuart J. Gallagher, Peter Hersey · 2014 · Pigment Cell & Melanoma Research
  73. Genome-Wide DNA Methylation Analysis in Melanoma Reveals the Importance of CpG Methylation in MITF Regulation
    Martin Lauss, Rizwan Haq, Helena Cirenajwis, Bengt Phung, Katja Harbst, Johan Staaf, Frida Rosengren, Karolina Holm, Mattias Aine, Karin Jirström et al. · 2015 · Journal of Investigative Dermatology
  74. Mutant HRAS as novel target for MEK and mTOR inhibitors
    M. Kiessling, Alessandra Curioni-Fontecedro, P. Samaras, K. Atrott, J. Cosin-Roger, S. Lang, M. Scharl, G. Rogler · 2015 · OncoTarget
  75. Unexpected UVR and non-UVR mutation burden in some acral and cutaneous melanomas
    Robert V. Rawson, Peter A. Johansson, Nicholas K. Hayward, Nicola Waddell, Ann‐Marie Patch, Serigne Lo, John V. Pearson, John F. Thompson, Graham J. Mann, Richard A. Scolyer et al. · 2017 · Laboratory Investigation
  76. Passenger mutations accurately classify human tumors
    Marina Salvadores, David Mas-Ponte, Fran Supek · 2019 · PLoS Computational Biology
  77. Cancer modeling by Transgene Electroporation in Adult Zebrafish (TEAZ)
    Scott J. Callahan, Stephanie Tepan, Yan M Zhang, Helen A. Lindsay, Alexa Burger, Nathaniel R. Campbell, Isabella S. Kim, Travis J. Hollmann, Lorenz Studer, Christian Mosimann et al. · 2018 · Disease Models & Mechanisms
  78. Pathophysiology, diagnosis and management of cardiac toxicity induced by immune checkpoint inhibitors and BRAF and MEK inhibitors
    Dimitri Arangalage, Nils Degrauwe, Olivier Alain Michielin, Pierre A Monney, Berna Cennet Özdemir · 2021 · Cancer Treatment Reviews
  79. Repair of UVB-induced DNA damage is reduced in melanoma due to low XPC and global genome repair
    Budden, Timothy, Davey, Ryan J., Vilain, Ricardo E., Ashton, Katie A., Braye, Stephen G., Beveridge, Natalie J., Bowden, Nikola A. · 2016 · Oncotarget
  80. The role of Rac in tumor susceptibility and disease progression: from biochemistry to the clinic
    Victoria Casado‐Medrano, Martin J. Baker, Cynthia López‐Haber, Mariana Cooke, Shaofei Wang, Marı́a J. Caloca, Marcelo G. Kazanietz · 2018 · Biochemical Society Transactions
  81. Integrative molecular and clinical profiling of acral melanoma links focal amplification of 22q11.21 to metastasis
    Farshad Farshidfar, Kahn Rhrissorrakrai, Chaya Levovitz, Cong Peng, James Knight, Antonella Bacchiocchi, Juan Su, Mingzhu Yin, Mario Sznol, Stephan Ariyan et al. · 2022 · Nature Communications
  82. The DNA methylation landscape of human melanoma
    Seung‐Gi Jin, Wenying Xiong, Xiwei Wu, Lu Yang, Gerd P. Pfeifer · 2015 · Genomics
  83. Rho GEFs and Cancer: Linking Gene Expression and Metastatic Dissemination
    Laura Barrio‐Real, Marcelo G. Kazanietz · 2012 · Science Signaling
  84. SHP2 phosphatase as a novel therapeutic target for melanoma treatment
    Ruoyu Zhang, Zhi-Hong Yu, Li‐Fan Zeng, Sheng Zhang, Yunpeng Bai, Jinmin Miao, Lan Chen, Jingwu Xie, Zhong‐Yin Zhang · 2016 · Oncotarget
  85. Plasma Circulating Tumor DNA Levels for the Monitoring of Melanoma Patients: Landscape of Available Technologies and Clinical Applications
    Benoît Busser, Julien Lupo, Lucie Sancey, Stéphane Mouret, Patrice Faure, Joël Plumas, Laurence Chaperot, M.‐T. Leccia, Jean‐Luc Coll, Amandine Hurbin et al. · 2017 · BioMed Research International
  86. Suppression of RAC1-driven malignant melanoma by group A PAK inhibitors
    Daniela Araiza‐Olivera, Yayi Feng, Galina Semenova, Tatiana Y. Prudnikova, Jennifer Rhodes, Jonathan Chernoff · 2017 · Oncogene
  87. Mitochondrial transcription factor A (TFAM) shapes metabolic and invasion gene signatures in melanoma
    Luíza Ferreira de Araújo, Ádamo Davi Diógenes Siena, Jéssica Rodrigues Plaça, Danielle Barbosa Brotto, Isabela Ichihara de Barros, Bruna Rodrigues Muys, Carlos Alberto Oliveira de Biagi, Kamila Chagas Peronni, Josane F. Sousa, Greice Andreotti de Molfetta et al. · 2018 · Scientific Reports
  88. Keratin 17 is a sensitive and specific biomarker of urothelial neoplasia
    Sruthi Babu, Daniel C. Mockler, Lucia Roa‐Peña, Agnieszka Szygalowicz, Nam W. Kim, Sholeh Jahanfard, Shahram S. Gholami, Richard A. Moffitt, John P. Fitzgerald, Luisa F. Escobar‐Hoyos et al. · 2018 · Modern Pathology
  89. New strategy for the gene mutation identification using surface enhanced Raman spectroscopy (SERS)
    Agata Kowalczyk, Jan Krajczewski, Artur Kowalik, J.L. Weyher, Igor Dzięcielewski, Małgorzata Chłopek, Stanisław S. Góźdź, Anna Maria Nowicka, Andrzej Kudelski · 2019 · Biosensors and Bioelectronics
  90. Adaptive Resistance to Dual BRAF/MEK Inhibition in BRAF-Driven Tumors through Autocrine FGFR Pathway Activation
    Victoria E. H. Wang, Jenny Y. Xue, Dennie Tompers Frederick, Yi Cao, Eva Lin, Catherine Wilson, Anatoly Urisman, David Paul Carbone, Keith T. Flaherty, René Bernards et al. · 2019 · Clinical Cancer Research
  91. Melanoma: Clinical Features and Genomic Insights
    Elena B. Hawryluk, Hensin Tsao · 2014 · Cold Spring Harbor Perspectives in Medicine
  92. Exploiting TERT dependency as a therapeutic strategy for NRAS-mutant melanoma
    Patricia I. Reyes-Uribe, Maria Paz Adrianzen-Ruesta, Zhong Deng, Ileabett M. Echevarría-Vargas, Ilgen Mender, Steven Saheb, Qin Liu, Dario C. Altieri, Maureen E. Murphy, Jerry W. Shay et al. · 2018 · Oncogene
  93. Automated Tracking of Nanoparticle-labeled Melanoma Cells Improves the Predictive Power of a Brain Metastasis Model
    Terje Sundstrøm, Inderjit Daphu, INGVILD HAUKAAS WENDELBO, Erlend Hodneland, Arvid Lundervold, Heike Immervoll, Kai Ove Skaftnesmo, Michal Babič, Pavla Jendelová, Eva Syková et al. · 2013 · Cancer Research
  94. ROCK1 is a potential combinatorial drug target for BRAF mutant melanoma
    Marjon A. Smit, Gianluca Maddalo, Kylie T. Greig, Linsey M. Raaijmakers, Patrícia A. Possik, Bas van Breukelen, Salvatore Cappadona, Albert J. R. Heck, Maarten A. F. Altelaar, Daniel S. Peeper · 2014 · Molecular Systems Biology
  95. Next-Generation Sequencing and Applications to the Diagnosis and Treatment of Lung Cancer
    Kristina M. Kruglyak, Erick Lin, Frank Shih-Chang Ong · 2015 · Advances in experimental medicine and biology
  96. Neural crest stem cells in melanoma development
    Olga Shakhova · 2014 · Current Opinion in Oncology
  97. Ultraviolet light and melanoma
    Sarah Craig, Charles H. Earnshaw, Amaya Virós · 2018 · The Journal of Pathology
  98. Melanoma cell adhesion molecule is the driving force behind the dissemination of melanoma upon S100A8/A9 binding in the original skin lesion
    Youyi Chen, I Wayan Sumardika, Nahoko Tomonobu, I Made Winarsa Ruma, Rie Kinoshita, Eisaku Kondo, Yusuke Inoue, Hiroki Sato, 明 山内, Hitoshi Murata et al. · 2019 · Cancer Letters
  99. TRPML1 Promotes Protein Homeostasis in Melanoma Cells by Negatively Regulating MAPK and mTORC1 Signaling
    Stacy Y. Kasitinon, Uğur Eskiocak, Misty Martin, Divya Bezwada, Vishal Khivansara, Alpaslan Tasdogan, Zhiyu Zhao, Thomas P. Mathews, Arin B. Aurora, Sean J. Morrison · 2019 · Cell Reports
  100. Hypoxia‐induced HIF 1α targets in melanocytes reveal a molecular profile associated with poor melanoma prognosis
    Stacie K. Loftus, Laura L. Baxter, Julia C. Cronin, Temesgen Fufa, NISC Comparative Sequencing Program, William J. Pavan · 2017 · Pigment Cell & Melanoma Research